Pyronaridine: an effective antimalarial against multidrug-resistant malaria.
Pyronaridine, administered intramuscularly (im) to Swiss mice infected with the lethal multidrug-resistant Plasmodium yoelii nigeriensis, was found to exert high blood schizontocidal activity. The efficacy of doses of pyronaridine ranging from 0.625 to 30 mg (base/kg) was evaluated using a 4 day treatment schedule (drug was administered at 0, 24, 48 and 72 hrs). It was found that doses of 2.5mg/ kg and higher protected animals completely from the lethal effects of the parasite. The same degree of protection was found when the treatment duration was reduced to 3 days. This study shows that pyronaridine is a potentially useful antimalarial drug that could be exploited for the control of multidrug-resistant malaria infection.
Dutta
G P
GP
Division of Microbiology and Parasitology, Central Drug Research Institute, Lucknow, India.
Puri
S K
SK
Awasthi
A
A
Mishra
M
M
Tripathi
R
R
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D018432:Drug Resistance, Multiple; D008288:Malaria / Q000097:blood / Q000188:drug therapy*; D051379:Mice; D009287:Naphthyridines / Q000097:blood / Q000494:pharmacology*; D010967:Plasmodium yoelii
D000962:Antimalarials; D009287:Naphthyridines; C027871:pyronaridine